{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T03:16:18Z","timestamp":1783048578970,"version":"3.54.6"},"reference-count":48,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"publisher","award":["31311"],"award-info":[{"award-number":["31311"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.humimm.2026.111724","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T01:33:00Z","timestamp":1777080780000},"page":"111724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Activating KIR3DS1: A key driver of KIR3DL1\/HLA-Bw4-linked risk in CML"],"prefix":"10.1016","volume":"87","author":[{"given":"Masoumeh","family":"Basirat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maral","family":"Mokhtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2024-191X","authenticated-orcid":false,"given":"Hassan Ghader","family":"Abadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1369-8466","authenticated-orcid":false,"given":"Shirin","family":"Farjadian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.humimm.2026.111724_b0005","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1186\/s12885-024-12764-y","article-title":"Application of artificial intelligence in chronic myeloid leukemia (CML) disease prediction and management: a scoping review","volume":"24","author":"Ram","year":"2024","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.humimm.2026.111724_b0010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/hematolrep17020018","article-title":"Genetic profiling of acute and chronic leukemia via next-generation sequencing: current insights and future perspectives","volume":"17","author":"Pratiwi","year":"2025","journal-title":"Hematol. Rep."},{"issue":"11","key":"10.1016\/j.humimm.2026.111724_b0015","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"Suppl 2","key":"10.1016\/j.humimm.2026.111724_b0020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia: an update","volume":"94","author":"H\u00f6glund","year":"2015","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.humimm.2026.111724_b0025","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1186\/s13287-021-02659-1","article-title":"Chronic myeloid leukemia stem cells: targeting therapeutic implications","volume":"12","author":"Mojtahedi","year":"2021","journal-title":"Stem Cell Res Ther"},{"issue":"12","key":"10.1016\/j.humimm.2026.111724_b0030","first-page":"1595","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood, the Journal of the American Society of Hematology."},{"issue":"1","key":"10.1016\/j.humimm.2026.111724_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-025-03375-x","article-title":"Natural killer cells: the immune frontline against circulating tumor cells","volume":"44","author":"Masmoudi","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.humimm.2026.111724_b0040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12985-024-02287-0","article-title":"Unraveling the dynamic mechanisms of natural killer cells in viral infections: insights and implications","volume":"21","author":"Letafati","year":"2024","journal-title":"Virol. J."},{"key":"10.1016\/j.humimm.2026.111724_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.913215","article-title":"From CD16a biology to antibody-dependent cell-mediated cytotoxicity improvement","volume":"13","author":"Co\u00ebnon","year":"2022","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.humimm.2026.111724_b0050","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1084\/jem.188.12.2375","article-title":"Natural killer (NK) cell\u2013mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells","volume":"188","author":"Zamai","year":"1998","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.humimm.2026.111724_b0055","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.humimm.2026.111724_b0060","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3390\/immuno1030021","article-title":"Role of KIR receptor in NK regulation during viral infections","volume":"1","author":"Rizzo","year":"2021","journal-title":"Immuno"},{"key":"10.1016\/j.humimm.2026.111724_b0065","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3389\/fimmu.2019.01179","article-title":"Killer Ig-like receptors (KIRs): their role in NK cell modulation and developments leading to their clinical exploitation","volume":"10","author":"Pende","year":"2019","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.humimm.2026.111724_b0070","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00251-009-0378-7","article-title":"KIR gene content diversity in four iranian populations","volume":"61","author":"Ashouri","year":"2009","journal-title":"Immunogenetics"},{"issue":"3","key":"10.1016\/j.humimm.2026.111724_b0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2567.2010.03398.x","article-title":"Structure\/function of human killer cell immunoglobulin\u2010like receptors: lessons from polymorphisms, evolution, crystal structures and mutations","volume":"132","author":"Campbell","year":"2011","journal-title":"Immunology"},{"issue":"23","key":"10.1016\/j.humimm.2026.111724_b0080","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.4161\/cbt.8.23.10455","article-title":"Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR)","volume":"8","author":"Purdy","year":"2009","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.humimm.2026.111724_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2007.03424.x","article-title":"Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease","volume":"149","author":"Boyton","year":"2007","journal-title":"Clinical & Experimental Immunology."},{"issue":"4","key":"10.1016\/j.humimm.2026.111724_b0090","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00262-016-1806-9","article-title":"Killer-cell immunoglobulin-like receptor genes and ligands and their role in hematologic malignancies","volume":"65","author":"Varbanova","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"issue":"12","key":"10.1016\/j.humimm.2026.111724_b0095","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1038\/sj.leu.2403525","article-title":"Identification of natural killer cell receptor phenotypes associated with leukemia","volume":"18","author":"Verheyden","year":"2004","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.humimm.2026.111724_b0100","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/iji.12509","article-title":"Association of killer\u2010cell immunoglobulin\u2010like receptor genes with acute myelogenous leukaemia","volume":"47","author":"Alavianmehr","year":"2020","journal-title":"Int. J. Immunogenet."},{"issue":"5","key":"10.1016\/j.humimm.2026.111724_b0105","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1399-0039.2007.00923.x","article-title":"Facilitation of KIR genotyping by a PCR\u2010SSP method that amplifies short DNA fragments","volume":"70","author":"Vilches","year":"2007","journal-title":"Tissue Antigens"},{"issue":"1","key":"10.1016\/j.humimm.2026.111724_b0110","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1399-0039.2009.01259.x","article-title":"A novel duplex SSP\u2013PCR typing method for KIR gene profiling","volume":"74","author":"Ashouri","year":"2009","journal-title":"Tissue Antigens"},{"issue":"3","key":"10.1016\/j.humimm.2026.111724_b0115","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1744-313X.2010.00906.x","article-title":"Compound KIR\u2010HLA genotype analyses in the iranian population by a novel PCR\u2013SSP assay","volume":"37","author":"Tajik","year":"2010","journal-title":"Int. J. Immunogenet."},{"issue":"1","key":"10.1016\/j.humimm.2026.111724_b0120","doi-asserted-by":"crossref","first-page":"11456","DOI":"10.1038\/s41598-023-38479-x","article-title":"Association of killer cell immunoglobulin-like receptors and their cognate HLA class I ligands with susceptibility to acute myeloid leukemia in iranian patients","volume":"13","author":"Mirzazadeh","year":"2023","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.humimm.2026.111724_b0125","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.it.2017.12.001","article-title":"Natural killer cell education and the response to infection and cancer therapy: stay tuned","volume":"39","author":"Boudreau","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.humimm.2026.111724_b0130","unstructured":"Society AC. Key Statistics for Chronic Myeloid Leukemia (CML) 2026 [Available from: https:\/\/www.cancer.org\/cancer\/types\/chronic-myeloid-leukemia\/about\/statistics.html?utm_source=chatgpt.com."},{"issue":"10","key":"10.1016\/j.humimm.2026.111724_b0135","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.humimm.2026.111724_b0140","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.humimm.2014.04.004","article-title":"Killer cell immunoglobulin-like receptors in Thai patients with leukemia and diffuse large B-cell lymphoma","volume":"75","author":"Vejbaesya","year":"2014","journal-title":"Hum. Immunol."},{"issue":"15","key":"10.1016\/j.humimm.2026.111724_b0145","first-page":"1699","article-title":"Racial and ethnic disparities in hematologic malignancies","volume":"130","author":"Kirtane","year":"2017","journal-title":"Blood, the Journal of the American Society of Hematology."},{"issue":"2","key":"10.1016\/j.humimm.2026.111724_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2024.110750","article-title":"Activating KIR\/HLA-I combinations as a risk factor of adult B-ALL","volume":"85","author":"Halimi","year":"2024","journal-title":"Hum. Immunol."},{"issue":"5","key":"10.1016\/j.humimm.2026.111724_b0155","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.exphem.2013.01.008","article-title":"Homozygosity for killer immunoglobin-like receptor haplotype a predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients","volume":"41","author":"La Nasa","year":"2013","journal-title":"Exp. Hematol."},{"issue":"6","key":"10.1016\/j.humimm.2026.111724_b0160","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1399-0039.2009.01235.x","article-title":"Killer immunoglobulin\u2010like receptors (KIR2DL2 and\/or KIR2DS2) in presence of their ligand (HLA\u2010C1 group) protect against chronic myeloid leukaemia","volume":"73","author":"Middleton","year":"2009","journal-title":"Tissue Antigens"},{"issue":"1","key":"10.1016\/j.humimm.2026.111724_b0165","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.leukres.2009.04.022","article-title":"Killer cell immunoglobulin-like receptor gene polymorphisms in patients with leukemia: possible association with susceptibility to the disease","volume":"34","author":"Zhang","year":"2010","journal-title":"Leuk. Res."},{"issue":"11","key":"10.1016\/j.humimm.2026.111724_b0170","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1038\/leu.2008.108","article-title":"Association of KIR2DS4 and its variant KIR1D with leukemia","volume":"22","author":"Giebel","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.humimm.2026.111724_b0175","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41435-020-00117-1","article-title":"Diversity of KIRs in invasive breast cancer patients and healthy controls along with the clinical significance in ER\/PR\/HER2+ patients","volume":"21","author":"Hematian Larki","year":"2020","journal-title":"Genes & Immunity."},{"issue":"3","key":"10.1016\/j.humimm.2026.111724_b0180","first-page":"536","article-title":"Killer cell immunoglobulin-like receptor gene cluster predisposes to susceptibility to B-cell acute lymphoblastic leukemia in chinese children","volume":"13","author":"Jiang","year":"2020","journal-title":"Int. J. Clin. Exp. Path."},{"issue":"5","key":"10.1016\/j.humimm.2026.111724_b0185","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.imbio.2019.06.002","article-title":"Activating and inhibitory killer cell immunoglobulin like receptors (KIR) genes are involved in an increased susceptibility to colorectal adenocarcinoma and protection against invasion and metastasis","volume":"224","author":"Barani","year":"2019","journal-title":"Immunobiology"},{"issue":"4","key":"10.1016\/j.humimm.2026.111724_b0190","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.humimm.2018.01.012","article-title":"KIR2DS1, 2DS5, 3DS1 and KIR2DL5 are associated with the risk of head and neck squamous cell carcinoma in Iranians","volume":"79","author":"Barani","year":"2018","journal-title":"Hum. Immunol."},{"issue":"5","key":"10.1016\/j.humimm.2026.111724_b0195","first-page":"1323","article-title":"Novel associations between activating killer-cell immunoglobulin-like receptor genes and childhood leukemia","volume":"118","author":"Almalte","year":"2011","journal-title":"Blood, the Journal of the American Society of Hematology."},{"issue":"1","key":"10.1016\/j.humimm.2026.111724_b0200","doi-asserted-by":"crossref","first-page":"7932","DOI":"10.1038\/s41598-021-86964-y","article-title":"Coexistence of inhibitory and activating killer-cell immunoglobulin-like receptors to the same cognate HLA-C2 and Bw4 ligands confer breast cancer risk","volume":"11","author":"Ashouri","year":"2021","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.humimm.2026.111724_b0205","first-page":"238","article-title":"Certain killer immunoglobulin-like receptor (KIR)\/KIR HLA class I ligand genotypes influence natural killer antitumor activity in myelogenous leukemia but not in acute lymphoblastic leukemia: a case control leukemia association study","volume":"36","author":"Varbanova","year":"2019","journal-title":"Turk. J. Hematol."},{"issue":"1","key":"10.1016\/j.humimm.2026.111724_b0210","first-page":"8","article-title":"KIR2DS3 is associated with protection against acute myeloid leukemia","volume":"7","author":"Shahsavar","year":"2010","journal-title":"Iran. J. Immunol."},{"issue":"2","key":"10.1016\/j.humimm.2026.111724_b0215","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1399-0039.2011.01721.x","article-title":"KIR\/HLA gene combinations influence susceptibility to B\u2010cell chronic lymphocytic leukemia and the clinical course of disease","volume":"78","author":"Karabon","year":"2011","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.humimm.2026.111724_b0220","doi-asserted-by":"crossref","unstructured":"Caocci G, Martino B, Greco M, Abruzzese E, Trawinska MM, Lai S, et al. Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients. Experimental hematology. 2015;43(12):1015-8. e1.","DOI":"10.1016\/j.exphem.2015.08.004"},{"key":"10.1016\/j.humimm.2026.111724_b0225","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3389\/fimmu.2014.00184","article-title":"Activating killer cell Ig-like receptors in health and disease","volume":"5","author":"Ivarsson","year":"2014","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.humimm.2026.111724_b0230","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1182\/blood-2005-03-0918","article-title":"Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand\u2013expressing tumor cells","volume":"106","author":"Coudert","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.humimm.2026.111724_b0235","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12967-015-0535-8","volume":"13","author":"Verma","year":"2015","journal-title":"J. Transl. Med."},{"issue":"8","key":"10.1016\/j.humimm.2026.111724_b0240","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1084\/jem.20072448","article-title":"Tolerance of NK cells encountering their viral ligand during development","volume":"205","author":"Sun","year":"2008","journal-title":"J. Exp. Med."}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885926000704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885926000704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T02:27:43Z","timestamp":1783045663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0198885926000704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0198885926000704"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2026.111724","relation":{},"ISSN":["0198-8859"],"issn-type":[{"value":"0198-8859","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activating KIR3DS1: A key driver of KIR3DL1\/HLA-Bw4-linked risk in CML","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2026.111724","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Society for Histocompatibility and Immunogenetics.","name":"copyright","label":"Copyright"}],"article-number":"111724"}}